THE CANADIAN PATENTED MEDICINE PRICES REVIEW BOARD - NEW RULES AND NEW STATUS

被引：2

作者：

SHULMAN, SR

机构：

[1] Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, 02111, 192 South St

来源：

PHARMACOECONOMICS | 1994年 / 6卷

关键词：

D O I：

10.2165/00019053-199400061-00017

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

The influence of the Patented Medicine Prices Review Board in restraining the prices of patented drugs has been established over the past 6 years. Recent legislative and policy changes now in place may result in the Board assuming a more influential, public, and activist posture. This article reviews the way in which the Board carries out its mandate to ensure that patented medicines sold in Canada are not 'excessive'. The Board represents one segment of Canada's ongoing effort to balance what often appear to be irreconcilable tasks - the promotion of an increased domestic research and development investment by the pharmaceutical industry, and the control of expenditures for pharmaceuticals in response to the escalating concerns of the provincial health authorities and consumers.

引用

页码：71 / 79

页数：9

共 11 条

[1]

Prescription drug prices — analysis of Canada’s Patented Medicine Prices Review Board, GAO/HRD-93-51, (1993)

[2]

PharmacoEconomics, 1, 1, (1992)

[3]

The President’s Health Security Plan, (1993)

[4]

Shulman S.R., Richard B.W., The 1987 Canadian patent law amendments: revised pharmaceutical compulsory licensing provisions, Food Drug Cosmetic Law Journal, 43, pp. 745-757, (1988)

[5]

Potential impact on the US economy and selected industries of the North American Free Trade Agreement, USITC Publication 2596, pp. 9-13, (1993)

[6]

Brogan T., Stronger patents and curbs on pricing in Canada, SCRIP Magazine, pp. 55-58, (1992)

[7]

Seminar IV — PMPRB new policies & pricing rules. Montreal, Quebec, September 22, (1993)

[8]

World Pharmaceutical Report, 1, 17, (1993)

[9]

Brogan T., Pharmacoeconomics — the Canadian experience, SCRIP Magazine, (1993)

[10]

Detsky A.S., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, pp. 354-361, (1993)

← 1 2 →